Ginger extract inhibits c-MET activation and suppresses osteosarcoma in vitro and in vivo DOI Creative Commons

Ruoping Yanzhang,

Mingyang Yan,

Zhaojie Yang

и другие.

Cancer Cell International, Год журнала: 2025, Номер 25(1)

Опубликована: Апрель 4, 2025

Osteosarcoma (OS) as an invasive and lethal malignancy showing a low 5-year survival rate requires novel therapeutic targets their suppressors to improve prevention treatment strategies. Our research served clarify the potential of ginger extract its underlying antineoplastic mechanisms in OS. In vitro studies were used detect anti-proliferation ability towards OS cells. Patient-derived xenograft (PDX) was performed confirm whether suppressed tumor growth. Cancer Heat Shock Protein (HSP) database utilized identify target extract, which subsequently validated through computational docking model screening method, molecular dynamics simulations pull-down assay. Analysis Gene Expression Omnibus (GEO) revealed c-MET expression among samples well mechanism. Immunohistochemistry (IHC) staining corroborated level tissues relative controls. Functional involving knockdown cell lines produced elucidate functional role cellular processes. demonstrated that administration impeded progress while inducing apoptosis inhibiting migration. Moreover, vivo tests unveiled prominently inhibited patient-derived development. HSP analysis recognized screening, combined with immunohistochemistry overexpression contrast Next, our study confirmed significant suppression anchorage-independent growth, concomitantly after knockdown, underscoring prospect for target. Collectively, findings show is prospective Ginger natural inhibitor, exhibits potent effects by suppressing growth both vivo, highlighting new agent this aggressive malignancy.

Язык: Английский

Target-based drug design strategies to overcome resistance to antiviral agents: opportunities and challenges DOI
Shaoqing Du, Xueping Hu, Luis Menéndez‐Arias

и другие.

Drug Resistance Updates, Год журнала: 2024, Номер 73, С. 101053 - 101053

Опубликована: Янв. 26, 2024

Язык: Английский

Процитировано

20
Antimicrobial Potential of Polyphenols: Mechanisms of Action and Microbial Responses—A Narrative Review DOI Creative Commons
Luca Rossi, Gabriele Rocchetti, Luigi Lucini

и другие.

Antioxidants, Год журнала: 2025, Номер 14(2), С. 200 - 200

Опубликована: Фев. 10, 2025

Polyphenols (PPs) are recognized as bioactive compounds and antimicrobial agents, playing a critical role in enhancing food safety, preservation, extending shelf life. The effectiveness of PPs has different molecular biological reasons, predominantly linked to their hydroxyl groups electron delocalization, which interact with microbial cell membranes, proteins, organelles. These interactions may reduce the efficiency metabolic pathways, cause destructive damage membrane, or they harm proteins nucleic acids foodborne bacteria. Moreover, exhibit distinctive ability form complexes metal ions, further amplifying activity. This narrative review explores complex multifaceted between pathogens, underlying correlation chemical structures mechanisms action. Such insights shed light on potential innovative natural preservatives within systems, presenting an eco-friendly sustainable alternative synthetic additives.

Язык: Английский

Процитировано

15
Botanical Flavonoids: Efficacy, Absorption, Metabolism and Advanced Pharmaceutical Technology for Improving Bioavailability DOI Creative Commons
Lei Hu, Yongming Luo, Jiaxin Yang

и другие.

Molecules, Год журнала: 2025, Номер 30(5), С. 1184 - 1184

Опубликована: Март 6, 2025

Flavonoids represent a class of natural plant secondary metabolites with multiple activities including antioxidant, antitumor, anti-inflammatory, and antimicrobial properties. However, due to their structural characteristics, they often exhibit low bioavailability in vivo. In this review, we focus on the vivo study flavonoids, particularly effects gut microbiome common modifications such as methylation, acetylation, dehydroxylation, etc. These aim change characteristics original substances enhance absorption bioavailability. order improve discuss two feasible methods, namely dosage form modification chemical modification, hope that these approaches will offer new insights into application flavonoids for human health. article, also introduce types, sources, efficacy flavonoids. conclusion, is comprehensive review how

Язык: Английский

Процитировано

5
The efflux pump ABCC1/MRP1 constitutively restricts PROTAC sensitivity in cancer cells DOI Creative Commons
Gernot Wolf, Conner Craigon, Shao Thing Teoh

и другие.

Cell chemical biology, Год журнала: 2025, Номер unknown

Опубликована: Янв. 1, 2025

Proteolysis targeting chimeras (PROTACs) are bifunctional molecules that induce selective protein degradation by linking an E3 ubiquitin ligase enzyme to a target protein. This approach allows scope for "undruggable" proteins, and several PROTACs have reached the stage of clinical candidates. However, roles cellular transmembrane transporters in PROTAC uptake efflux remain underexplored. Here, we utilized transporter-focused genetic screens identify ATP-binding cassette transporter ABCC1/MRP1 as key resistance factor. Unlike previously identified inducible exporter ABCB1/MDR1, ABCC1 is highly expressed among cancers various origins constitutively restricts bioavailability. Moreover, genome-wide screen, candidates involved processes such ubiquitination, mTOR signaling, apoptosis factors resistance. In summary, our findings reveal crucial active pump limiting efficacy cancer cells, offering insights overcoming drug

Язык: Английский

Процитировано

4
Nanoparticles for efficient drug delivery and drug resistance in glioma: New perspectives DOI
Jiyuan Liu, Fan Yang, Jinqu Hu

и другие.

CNS Neuroscience & Therapeutics, Год журнала: 2024, Номер 30(5)

Опубликована: Май 1, 2024

Abstract Gliomas are the most common primary tumors of central nervous system, with glioblastoma multiforme (GBM) having highest incidence, and their therapeutic efficacy depends primarily on extent surgical resection postoperative chemotherapy. The role intracranial blood–brain barrier occurrence drug‐resistant gene O6‐methylguanine‐DNA methyltransferase have greatly limited chemotherapeutic agents in patients GBM made it difficult to achieve expected clinical response. In recent years, rapid development nanotechnology has brought new hope for treatment tumors. Nanoparticles (NPs) shown great potential tumor therapy due unique properties such as light, heat, electromagnetic effects, passive targeting. Furthermore, NPs can effectively load drugs, significantly reduce side effects improve efficacy, showing chemotherapy glioma. this article, we reviewed mechanisms glioma drug resistance, physicochemical NPs, advances resistance. We aimed provide perspectives

Язык: Английский

Процитировано

12
ABCB1-dependent collateral sensitivity of multidrug-resistant colorectal cancer cells to the survivin inhibitor MX106-4C DOI
Zi‐Ning Lei,

Najah Albadari,

Qiu-Xu Teng

и другие.

Drug Resistance Updates, Год журнала: 2024, Номер 73, С. 101065 - 101065

Опубликована: Фев. 6, 2024

Язык: Английский

Процитировано

11
Extracellular Vesicles as Mediators and Potential Targets in Combating Cancer Drug Resistance DOI Creative Commons
Haodong Zhang, Bohan Wu, Y. N. Wang

и другие.

Molecules, Год журнала: 2025, Номер 30(3), С. 498 - 498

Опубликована: Янв. 23, 2025

Extracellular vesicles (EVs) are key mediators in the communication between cancer cells and their microenvironment, significantly influencing drug resistance. This review provides a comprehensive analysis of roles EVs promoting resistance through mechanisms such as efflux, apoptosis resistance, autophagy imbalance, tumor microenvironment modulation. Despite extensive research, details biogenesis, cargo selection, specific pathways EVs-mediated not fully understood. critically examines recent advancements, highlighting studies that elucidate molecular functions. Additionally, innovative therapeutic strategies targeting explored, including inhibiting engineering for delivery, identifying resistance-inhibiting molecules within EVs. By integrating insights from primary research proposing new directions future studies, this aims to advance understanding biology foster effective interventions mitigate therapy.

Язык: Английский

Процитировано

2
Overcoming cancer therapy resistance: From drug innovation to therapeutics DOI

Jinrui Wei,

Meng‐Yi Lu,

Tian‐Hua Wei

и другие.

Drug Resistance Updates, Год журнала: 2025, Номер 81, С. 101229 - 101229

Опубликована: Март 8, 2025

Язык: Английский

Процитировано

2
Effective therapy of advanced breast cancer through synergistic anticancer by paclitaxel and P-glycoprotein inhibitor DOI Creative Commons
Sifeng Zhu, Chao Sun,

Zimin Cai

и другие.

Materials Today Bio, Год журнала: 2024, Номер 26, С. 101029 - 101029

Опубликована: Март 19, 2024

Multi-drug resistance (MDR) in advanced breast cancer (ABC) is triggered by the high expression of P-glycoprotein (P-gp), which reduces intracellular concentration anti-tumor drugs, turn preventing oxidative stress damage to cytoplasmic and mitochondrial membranes. It therefore clinical relevance develop P-gp-specific targeted nanocarriers for treatment drug resistant ABC. Herein, a carrier targeting CD44 mitochondria was synthesised delivery encequidar (ER, P-gp inhibitor) paclitaxel (PTX). HT@ER/PTX nanoparticles (ER:PTX molar ratio 1:1) had excellent inhibition ability induce apoptosis MCF-7/PTX cells vitro. Furthermore, showed more efficacy than PTX (Taxol®) xenograft mouse model cells; tumor inhibitory rates Taxol® were 72.64% ± 4.41% 32.36% 4.09%, respectively. The survival tumor-bearing mice administered prolonged compared that treated with Taxol®. In addition, not only inhibited P-gp-mediated removal toxic lipid peroxidation byproducts resulting from drugs but also upregulated dynamics-related protein, fostering damage, induced activation Caspase-3 pathway. Our findings indicate co-delivery inhibitors could be practical approach treating multi-drug

Язык: Английский

Процитировано

9
Lycium barbarum polysaccharide reverses drug resistance in oxaliplatin-resistant colon cancer cells by inhibiting PI3K/AKT-dependent phosphomannose isomerase DOI Creative Commons
Lijun Ma,

Fangfang Ai,

Hongyan Xiao

и другие.

Frontiers in Pharmacology, Год журнала: 2024, Номер 15

Опубликована: Март 21, 2024

Objective: Here, we aimed to explore the effect of LBP in combination with Oxaliplatin (OXA) on reversing drug resistance colon cancer cells through vitro and vivo experiments. We also possible mechanism underlying this effect. Finally, determine potential targets Lycium barbarum polysaccharide (LBP) (CC) network pharmacology molecular docking. Methods: The invasion ability was assessed using assay. migration these assay wound healing Cell cycle analysis carried out flow cytometry. expression levels phosphomannose isomerase (PMI) ATP-binding cassette transport protein G2 (ABCG2) proteins were determined immunofluorescence western blotting. phosphatidylinositol3-kinase (PI3K), kinase B (AKT), B-cell lymphoma 2 (Bcl-2), BCL2-Associated X (Bax) Forty BALB/c nude mice purchased from Weitong Lihua, Beijing, for analyses. randomly divided into eight groups. They administered HCT116 HCT116-OXR prepare xenograft models then treated PBS, (50 mg/kg), OXA (10 or + mg/kg 10 mg/kg). tumor weight volume model measured, organ toxicity evaluated hematoxylin eosin staining. PMI, ABCG2, PI3K, AKT immunohistochemistry. Moreover, PMI ABCG2 analyzed active components explored silico analysis. GeneCards used identify CC targets, an online Venn tool intersection between components. PPI target interactions built STRING Cytoscape. To obtain putative CC, performed GO function enrichment KEGG pathway Results: Compared blank treatment group, both abilities inhibited (2.5 mg/mL LBP, μΜ OXA) group ( p < 0.05). Cells found arrest G1 phase cell cycle. Knockdown downregulate AKT, Bcl-2 0.05), while it upregulate Bax After L. polysaccharide, 40 subcutaneous showed a decrease size. There no difference liver index after > However, spleen decreased groups possibly as side oxaliplatin. Immunohistochemistry, immunofluorescence, blotting that immunohistochemistry PI3K Network revealed 45 components, including carotenoids, phenylpropanoids, quercetin, xanthophylls, other polyphenols. It 146 therapeutic SRC, EGFR, HRAS, STAT3, MAPK3. enriched pathways, cancer-related signaling PI3K/AKT pathway, IL-17 pathways. docking experiments bind well PMI. conclusion: Our knockdown downregulated upregulated Bax. This finding confirms plays role by regulating lays foundation study reversal OXA. combined oxaliplatin could inhibit growth. hepatic splenic toxicity. AKT; may thus have positive significance advanced metastatic cancer. core pathways they are in. further verified results our experiments, showing involvement multi-component, multi-target, multi-pathway synergism drug-reversing CC. Overall, findings present provide new avenues future clinical

Язык: Английский

Процитировано

7